Lv1
10 积分 2023-12-26 加入
Co-blocking TIGIT and PVRIG using a novel bispecific antibody enhances anti-tumor immunity
1天前
待确认
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader
1个月前
已完结
Targeting cancer with small molecule pan-KRAS degraders
2个月前
已完结
NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
3个月前
已完结
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
7个月前
已完结
Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data
9个月前
已完结
The therapeutic window of antibody drug conjugates: A dogma in need of revision
9个月前
已完结
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer
10个月前
已完结
Chromatin remodellers as therapeutic targets
10个月前
已完结
Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor
10个月前
已完结
皖公网安备34019202002308
